一心为民全心服务 第六届董事会第四次临时会议决议公告 1．审议通过《关于使用募集资金对全资子公司鸿翔中药有限公司增加注册资本的 议案》 《关于使用募集资金对全资子公司鸿翔中药有限公司增加注册资本的公告》详见公 司指定信息披露媒体《证券时报》、《中国证券报》、《证券日报》和巨潮资讯网 （www.cninfo.com.cn）。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一心堂药业集团股份有限公司（以下称"公司"）第六届董事会第四次临时会议于 2023 年 8 月 25 日 10 时以现场及通讯表决方式召开，本次会议于 2023 年 8 月 18 日通 过邮件及书面形式发出通知。本次会议应出席会议的董事为 9 人，实际出席会议的董事 为 9 人。公司监事及非董事高级管理人员列席了会议。本次会议的召开符合有关法律、 行政法规、部门规章、规范性文件和《公司章程》的规定。 会议由阮鸿献先生主持。与会董事逐项审议了有关议案并做出决议如下。 二、董事会会议审议情况 股票代码：002727 股票简称：一心堂 公告编号：2023-062 号 一心堂药 ...

东兴证券股份有限公司 关于一心堂药业集团股份有限公司 使用募集资金对全资子公司鸿翔中药有限公司增加注册资 本的核查意见 东兴证券股份有限公司（以下简称"保荐机构"、"东兴证券"）作为一心堂 药业集团股份有限公司（以下简称"一心堂"、"公司"）持续督导的保荐机构， 根据《深圳证券交易所股票上市规则（2023 年修订）》、《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等相关法规和规范性文件的要 求，对一心堂使用募集资金对全资子公司鸿翔中药有限公司增加注册资本事项进 行了核查，具体情况如下： 一、公司本次募集资金基本情况 经中国证券监督管理委员会于 2018 年 10 月 23 日出具的《关于核准云南鸿 翔一心堂药业（集团）股份有限公司公开发行可转换公司债券的批复》（证监许 可［2018］2160 号）核准，公司于 2019 年 4 月 19 日向社会公众公开发行面值 不超过 60,263.92 万元的可转换公司债券，每张面值 100 元，按面值平价发行， 发行总额 60,263.92 万元。上述募集资金总额扣除承销 ...

关于使用募集资金对全资子公司鸿翔中药有限公司 一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-063 号 一心堂药业集团股份有限公司 增加注册资本的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）第六届董事会第四次临时会议 于 2023 年 8 月 25 日 10 时整在公司会议室召开，以 9 票同意、0 票反对、0 票弃权审议 通过了《关于使用募集资金对全资子公司鸿翔中药有限公司增加注册资本的议案》。并 同意鸿翔中药有限公司（以下简称"鸿翔中药"）就本次增资修改《公司章程》。 现就相关情况公告如下： 一、公司本次募集资金基本情况 经中国证券监督管理委员会于 2018 年 10 月 23 日出具的《关于核准云南鸿翔一心 堂药业（集团）股份有限公司公开发行可转换公司债券的批复》（证监许可［2018］2160 号）核准，一心堂药业集团股份有限公司（以下简称："本公司"）于 2019 年 4 月 19 日向社会公众公开发行面值不超过 60,263.92万元的可转换公司债券，每张面值 ...

股票代码：002727 股票简称：一心堂 公告编号：2023-059 号 一心为民全心服务 一心堂药业集团股份有限公司 关于全资子公司鸿翔中药有限公司 一心为民全心服务 竞得土地使用权的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本情况概述 一心堂药业集团股份有限公司（以下简称"公司"）于 2023 年 6 月 20 日召开第六 届董事会第三次临时会议审议通过《关于同意公司全资子公司鸿翔中药有限公司与昆明 经济技术开发区管理委员会签订项目投资合作协议的议案》，同意全资子公司鸿翔中药 有限公司（以下简称"鸿翔中药"）与昆明经济技术开发区管理委员会（以下简称"经 开区管委会"）签订《项目投资合作协议》。鸿翔中药拟在昆明市经开区投资建设中药 饮片产能扩建项目，项目总投资 4 亿元，新建数字化智能制造中药饮片生产基地，建设 中药材、中药饮片数字化物流配送中心及第三方检验平台业务服务中心。经开区管委会 根据《中国（云南）自由贸易试验区昆明片区管理委员会昆明经济技术开发区管理委员 会关于印发促进产业高质量发展系列政策的通知》（昆自贸管〔2022〕1 号 ...

一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-024 号 一心堂药业集团股份有限公司 关于参加云南辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，一心堂药业集团股份有限公司（以下简称"公 司"）将参加由云南证监局、云南省上市公司协会与深圳市全景网络有限公司联合举办 的"2022 年度云南辖区上市公司投资者网上集体接待日暨集体业绩说明会"，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录" 全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参与 本次互动交流，活动时间为 2023 年 5 月 11 日（周四）10:30-12:00。届时公司高管将 在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和 可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参 与！ 特此公告！ 一心堂药业集团股份有限公司 董事 ...

Financial Performance - The company's total revenue for Q4 reached CNY 5,406,196,526.38, marking a significant increase compared to previous quarters[7] - Net profit attributable to shareholders for Q4 was CNY 332,630,300.61, reflecting a growth of approximately 28.3% from Q3[7] - Total revenue for 2022 reached ¥17,431,615,604.10, representing a year-on-year increase of 19.50% compared to ¥14,587,401,324.01 in 2021[58] - Net profit attributable to shareholders for 2022 was CNY 1,009,996,157.90, a 9.59% increase compared to CNY 921,583,567.71 in 2021[164] - The net profit after deducting non-recurring gains and losses was CNY 989,137,722.83, reflecting a 10.05% increase from CNY 898,786,415.52 in 2021[164] - The net cash flow from operating activities increased by 39.37% to CNY 2,497,100,478.58 from CNY 1,791,674,042.72 in the previous year[164] - Basic earnings per share for 2022 were CNY 1.7022, up 9.01% from CNY 1.5615 in 2021[164] - Total assets at the end of 2022 reached CNY 16,179,093,228.09, a 12.85% increase from CNY 14,337,349,279.85 at the end of 2021[164] - Net assets attributable to shareholders increased by 12.90% to CNY 7,426,145,337.11 from CNY 6,577,747,355.32 in 2021[164] Operational Strategies - The company is actively exploring new retail formats, including health food and personal care products, to enhance its service offerings[14] - The company plans to adopt innovative models such as smart pharmacies and DTP professional pharmacies to improve customer service[14] - The procurement strategy focuses on balancing inventory and ensuring quality control, utilizing a combination of centralized and regional purchasing[15] - The company implemented a single-store optimization plan to improve store performance, targeting key stores for enhancement and leveraging its integrated brand network[17] - The company expanded its multi-category business model, promoting sales of lottery and personal care products to attract a broader consumer base and increase store visit frequency[17] - The company is focusing on professional chronic disease management services as a core competitive advantage in the retail pharmacy sector[35] - The company aims to leverage its geographical advantages in Yunnan to strengthen its traditional Chinese medicine industry chain, which has significant growth potential[40] - The company has established a comprehensive training system to enhance core competencies in key positions, ensuring high service levels[35] Market Position and Expansion - The company ranked first in the 2021-2022 annual list of China's top 100 chain pharmacies, showcasing its market leadership[9] - The retail pharmacy sector in China saw a total sales revenue of CNY 248 billion in the first half of the year, with a year-on-year growth of 3.4%[9] - The company operates over 1,700 stores across various market levels, creating a unique multi-dimensional direct sales development pattern[28] - The company aims to maintain a high-density network of stores and achieve a leading market share in regional markets through standardized management[31] - The company has opened a total of 9,206 direct chain stores by the end of 2022, with 8,454 stores qualifying as "medical insurance designated retail pharmacies," representing 91.83% of total stores, an increase of 5 percentage points year-on-year[52] - The company has opened 459 new stores in Yunnan province, bringing the total to 5,224 stores, demonstrating a strong expansion strategy[50] Technology and Innovation - The company is leveraging technology such as AI and IoT to enhance retail operations and customer experience[14] - A digital management system was established to facilitate data-driven decision-making and enhance operational efficiency through detailed management[18] - The company has implemented a modern information technology system, including a leading D_ERP system, to enhance integrated management and operational efficiency[46] - The company has developed a comprehensive O2O business model, launching various WeChat mini-programs to enhance online and offline integration[46] Social Responsibility and Community Engagement - The company emphasizes its commitment to corporate social responsibility, including job creation and compliance with environmental policies[186] - Yunnan Yixintang has been involved in various social welfare initiatives, including disaster relief and educational support, through donations and community engagement[189] - The company actively supports the employment of disabled individuals, providing job opportunities and ensuring their legal rights are protected through contracts and benefits[191] - The company has conducted over 30,000 health clinics and nearly 1,500 charity events through its "Health Journey" initiative, benefiting over 100,000 impoverished members[189] Financial Management and Investments - The total investment cash outflow decreased by 48.38% to CNY 1,432,624,230.27 in 2022, down from CNY 2,775,535,059.46 in 2021[81] - The company has consistently returned temporarily used funds to the designated accounts within the stipulated 12-month period[111] - The total committed investment amount for projects is CNY 152 million, with an adjusted total of CNY 147.34 million[112] - The cumulative investment amount as of the end of the reporting period is CNY 88.52 million, representing an investment progress of 60.98%[112] - The company has completed all its investment projects without any litigation issues reported[121] Challenges and Future Outlook - The company has indicated uncertainty regarding its ability to continue as a going concern based on the latest audit report[164] - The retail pharmacy industry in China is experiencing low market concentration, with significant potential for future consolidation[118] - The company aims to adapt to the evolving market by enhancing service quality and operational efficiency in the competitive retail pharmacy landscape[136]